Skip to content
Pharma Observatory a Scientist.com platform

Organization (Academic)

China Academy of Chinese Medical Sciences

ClinicalTrials.gov lists China Academy of Chinese Medical Sciences as lead sponsor of 62 trials. It has 1 active development program and 29 approved assets.

CN Academic
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

11 0 2007 2026

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 3 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.8 trial starts a year over the five years to September, under the 5 a year the method needs.

This page covers China Academy of Chinese Medical Sciences: 62 lead-sponsored trials and 1 legal-entity registration.

Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.

Get the China Academy of Chinese Medical Sciences report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (137)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Pain 22
Coronary Disease 18
Angina Pectoris 15
Chest Pain 15
Arthritis, Rheumatoid 14

Trials by start year as sponsor or collaborator (17)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 3
2025 1
2023 1
2022 2
2021 4
2020 3
2019 8
2018 9
2017 6
2016 2

Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (1)

Active development programs
Drug Disease area Max phase Trials
Yiqi Fumai Lyophilized Injection Coronary Disease Not reported 2

Approved assets (29)

Shown in this order: max phase first.

Approved assets
Drug Trials
Standard Medical Care 5
Danhong Injection 4
Sanjin tablets 1
amoxil capsule simulator 1
Reyanning mixture simulator 1

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
2 of 3 hit target (n=3) 50% on time (n=6)

Journals published in (105)

Shown in this order: most published in first.

Journals published in
Journal Publications
Trials 20
Chinese journal of integrative medicine 13
Medicine 9
BMJ open 8
Evidence-based complementary and alternative medicine : eCAM 8

US granted patents (1)

Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.

US granted patents
US patents granted Granted in the last 5 years Most recent grant
2 0 2020-01-07

Organization relationships (52)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
Hebei Provincial Hospital of Traditional Chinese Medicine Co sponsors trial with 2
Tongji Hospital Co sponsors trial with 2
Jinan Central Hospital Co sponsors trial with 2
Fudan University Co sponsors trial with 1
First People's Hospital of Foshan Co sponsors trial with 1

Latest dated events (239)

Shown in this order: newest first.

Latest dated events
Date Event Source
2027-01-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-09 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-09 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-07-05 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-04 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Biomarker capability evidence (7)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
NPPB Trial sponsor Named in trial inclusion criteria
NPPB Trial sponsor Named in trial inclusion criteria
PSD Trial sponsor Named in trial inclusion criteria
NPPB Trial sponsor Exploratory endpoint in a trial
NPPB Trial sponsor Mentioned in trial text

Biomarkers this organization publishes on (318)

Shown in this order: most publications first.

Biomarkers this organization publishes on
Biomarker Publications
CRP 16
GPT 13
TNF 11
INS 10
FAS 9

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.